par Kaye, S B;Wanders, Jantien;Clavel, Michel;Verweij, Jaap;Piccart-Gebhart, Martine 
;Smyth, J F;ten Bokkel Huinink, Wim;Wagener, Th;Judson, I R;Cavalli, F
Référence Annals of oncology, 3, 5, page (406-408)
Publication Publié, 1992-05
;Smyth, J F;ten Bokkel Huinink, Wim;Wagener, Th;Judson, I R;Cavalli, FRéférence Annals of oncology, 3, 5, page (406-408)
Publication Publié, 1992-05
Article révisé par les pairs
| Résumé : | A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were breast (24), ovary (25), head and neck (21) and melanoma (21). All patients, except those with melanoma had received prior chemotherapy. The drug was given intravenously as a 20 min infusion, at the dose of 120 mg/m2 on days 1 to 5 of a 3 week cycle. Treatment was well tolerated; the only significant side-effects being mild headaches and generalised musculo-skeletal pains. Response was assessed after 2 cycles of therapy. Only one patient (with head and neck cancer) achieved an objective partial response, lasting 6 weeks. A total of 12 patients demonstrated stable disease for a median duration of 15 to 20 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours. |
